BridgeBio Pharma, Inc.
BBIO
$66.92
$0.971.47%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 26.16% | 27.74% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 26.16% | 27.74% | |||
| Cost of Revenue | 22.60% | 23.53% | |||
| Gross Profit | 26.36% | 27.98% | |||
| SG&A Expenses | 3.68% | 14.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.32% | 9.94% | |||
| Operating Income | 17.50% | 5.81% | |||
| Income Before Tax | 14.48% | -4.44% | |||
| Income Tax Expenses | -- | 92.23% | |||
| Earnings from Continuing Operations | 14.43% | -5.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 41.76% | -19.23% | |||
| Net Income | 14.94% | -5.54% | |||
| EBIT | 17.50% | 5.81% | |||
| EBITDA | 17.50% | 5.90% | |||
| EPS Basic | 15.48% | -4.61% | |||
| Normalized Basic EPS | 10.67% | -2.91% | |||
| EPS Diluted | 15.48% | -4.61% | |||
| Normalized Diluted EPS | 10.67% | -2.91% | |||
| Average Basic Shares Outstanding | 0.64% | 0.89% | |||
| Average Diluted Shares Outstanding | 0.64% | 0.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||